By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bionomics Limited 

31 Dalgleish Street

Thebarton  South Australia  5031  Australia
Phone: 618-8354-6100 Fax: 618-8354-6199




Nanogen, Inc.  Epilepsy diagnostic product development

Genmab A/S  Anti-angiogenesis therapeutic antibody development

Univ. of Melbourne, Women's & Children's Hospital 

Brigham and Women's Hospital 

Howard Florey Institute 

Company News
Bionomics Limited (BNO.AX): A Company With Deals On The Horizon 7/5/2017 6:24:16 AM
Bionomics Limited (BNO.AX) Release: New BNC105 Clinical Trial In Combination With Keytruda 2/20/2017 8:06:50 AM
Bionomics Limited (BNO.AX) To Receive Milestone Payment From Merck & Co. (MRK) For Initiation Of Phase I Clinical Study Of Candidate Alzheimer's Treatment 2/3/2017 7:39:45 AM
Bionomics Limited (BNO.AX) Announces Positive Results From Phase 2 Trial Of BNC210 In Generalized Anxiety Disorder 9/21/2016 8:52:51 AM
Bionomics Limited (BNO.AX) Release: Post Traumatic Stress Disorder Identified As Major New Market Opportunity For BNC210 12/8/2015 4:19:31 PM
Bionomics Limited (BNO.AX) And MSD Hosting Cognition And Alzheimer's Symposium Featuring Australian And US Speakers 11/13/2015 10:07:20 AM
Bionomics Limited (BNO.AX) To Present Preclinical Data On BNC105 At AACR-NCI-EORTC International Conference 11/4/2015 2:00:51 PM
Bionomics Limited (BNO.AX) Announces Extension Of Strategic Collaboration With Merck & Co. (MRK) For The Discovery And Development Of Novel Pain Medications 10/8/2015 6:26:45 AM
Bionomics Limited (BNO.AX) Reports Positive Data From Phase 1 Multiple Ascending Dose Trial Of BNC210 For Anxiety And Depression 9/16/2015 5:56:28 AM
Bionomics Limited (BNO.AX) Release: Successful BNC101 IND Submission Paves Way For Development Of Promising Cancer Stem Cell Drug Candidate 8/31/2015 6:39:02 AM